Trimel Pharmaceuticals (TRLPF) Cut to “Sell” at ValuEngine
ValuEngine downgraded shares of Trimel Pharmaceuticals (OTCMKTS:TRLPF) from a hold rating to a sell rating in a research note published on Sunday.
Trimel Pharmaceuticals (TRLPF) opened at $0.29 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.94 and a current ratio of 1.81. Trimel Pharmaceuticals has a 1 year low of $0.08 and a 1 year high of $0.40.
Trimel Pharmaceuticals Company Profile
Trimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men’s health, women’s health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Trimel Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trimel Pharmaceuticals Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.